BioIVT will help to generate drug discovery target validation data and characterize novel therapeutics
Royston, UK – Sept. 24, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined UK Medicines Discovery Catapult’s Discovery Services Platform, partnering with other best-in-class service providers to help improve preclinical drug discovery success rates.
From its GLP-accredited UK facility, BioIVT’s PHASEZERO® Research Services team will provide specialist support for generating human tissue-based target validation data and characterizing novel therapeutics. BioIVT’s research into such complex fields as immuno-oncology and fibrosis have given it the necessary experience to successfully validate associated drug targets and biomarkers and aid the development of novel therapeutics with the right balance of efficacy, disposition and safety.
“BioIVT is dedicated to supporting the research community by providing expertise in human tissue-based approaches that deliver target and biomarker validation data and by developing fit-for-purpose assays that enable characterization of novel therapeutics to accelerate drug discovery and development,” said Dr. Amanda Woodrooffe, Vice President and General Manager at BioIVT UK. “We are delighted to join Medicines Discovery Catapult’s Discovery Services Platform and be able to provide our expertise, access to ethically-sourced human biospecimens, and innovative approaches to support UK enterprises.”
In addition to its research services capabilities and expertise in the design, execution and delivery of industry-standard drug development data packages, BioIVT can provide ready access to well-characterized, consented human tissues, biofluids and primary cells in many disease areas. BioIVT is another strong and versatile addition to Medicines Discovery Catapult’s Discovery Services Platform.
Phone: (206) 992-5245